| Type 2 Diabetes Mellitus |
1 |
1 |
| SGLT2 Inhibitor |
0 |
0.99 |
| Heart Failure (HF) |
0 |
0.79 |
| Heart |
0 |
0.68 |
| Acute Heart Failure (HF) |
0 |
0.61 |
| Coronary Artery Disease (CAD) |
0 |
0.54 |
| Diabetic Cardiomyopathy |
0 |
0.98 |
| Cardiomyopathy |
0 |
0.49 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.48 |
| Cardiovascular Risk Management |
0 |
0.46 |
| Hypertension |
0 |
0.46 |
| Cardiovascular Imaging |
0 |
0.43 |
| ACE Inhibitor |
0 |
0.35 |
| Lipids Management |
0 |
0.32 |
| Biomarker |
0 |
0.26 |
| Hospital |
0 |
0.12 |
| Chronic Kidney Disease |
0 |
0.07 |
| Renal Failure |
0 |
0.07 |
| Kansas |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Renal Disease |
0 |
0.06 |
| Grant |
0 |
0.04 |
| Kidney |
0 |
0.04 |
| Kidney, Ureter, and Bladder |
0 |
0.04 |
| Angiotensin II Receptor Blockade |
0 |
0.03 |
| Body Mass Index |
0 |
0.03 |
| Cardiovascular disease |
0 |
0.03 |
| Clinical Guidelines |
0 |
0.03 |
| Ejection Fraction |
0 |
0.03 |
| Preventive Screening |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Stress |
0 |
0.03 |
| Texas |
0 |
0.03 |
| B-Type Natriuretic Peptide |
0 |
0.02 |
| Myocardial Infarction (MI) |
0 |
0.02 |
| Obesity |
0 |
0.02 |
| Peripheral Edema |
0 |
0.02 |
| Pulmonary Embolism |
0 |
0.02 |
| Adverse Effects |
0 |
0.01 |
| Artery |
0 |
0.01 |
| Blood |
0 |
0.01 |
| Brain |
0 |
0.01 |
| C-Reactive Protein (CRP) |
0 |
0.01 |
| California |
0 |
0.01 |
| Cerebrovascular Accident |
0 |
0.01 |
| Clinical Research |
0 |
0.01 |
| Connecticut |
0 |
0.01 |
| Deep Venous Thrombosis |
0 |
0.01 |
| Dorsum |
0 |
0.01 |
| Dyspnea |
0 |
0.01 |
| Edema |
0 |
0.01 |
| Electrocardiogram (ECG) |
0 |
0.01 |
| Electrophysiology |
0 |
0.01 |
| Fatigue |
0 |
0.01 |
| Fluid, Electrolyte, and Nutrition Management of the Newborn |
0 |
0.01 |
| Generics |
0 |
0.01 |
| Health Care Quality, Access, and Evaluation |
0 |
0.01 |
| Hemodynamics |
0 |
0.01 |
| Metabolism |
0 |
0.01 |
| Nutritional Support |
0 |
0.01 |
| Professional Societies |
0 |
0.01 |
| Social Determinants of Health |
0 |
0.01 |
| Statins |
0 |
0.01 |
| Statistics |
0 |
0.01 |
| Troponin |
0 |
0.01 |
| Weight Loss |
0 |
0.01 |
| Weight Management |
0 |
0.01 |